Memphasys Locks in $530K Vietnam Deal to Bring Felix Sperm Tech to SEA
Memphasys enters South-East Asia with A$530,000 Felix™ commercialisation agreement
Memphasys (ASX: MEM) has secured its first commercial partnership in South-East Asia, entering an exclusive two-year commercialisation agreement with TMSC Viet Nam Medical Technology Company Limited for the Felix™ sperm separation system in Vietnam. The agreement carries a total contracted value of A$530,000, structured as A$205,000 in Year 1 rising to A$325,000 in Year 2, with quarterly cartridge volume growth embedded in the contract. Vietnamese regulatory approval is expected in August 2026, after which full commercial sales can commence.
The deal extends Memphasys’ existing international network across Europe, MENA, Japan, and India into a new region.
When big ASX news breaks, our subscribers know first
Why Vietnam and why now
A high-growth IVF market with strong clinical infrastructure
Vietnam’s assisted reproductive technology sector represents a compelling commercial opportunity. The country’s IVF market was estimated at approximately US$141 million in 2023 and is forecast to exceed US$200 million by 2029, according to TechSci Research. Key growth drivers include:
- Rising infertility rates across the population
- Increasing government and private healthcare investment
- Growing patient demand for premium fertility services
- IVF success rates comparable to leading European and US centres
- Rapidly expanding fertility infrastructure across Hanoi and Ho Chi Minh City
Vietnam’s clinical maturity and accelerating demand for advanced sperm selection technologies position Felix™ for meaningful adoption as local clinics focus on improving IVF outcomes and laboratory efficiency.
About TMSC Vietnam
TMSC Viet Nam Medical Technology Company Limited is a Hanoi-based medical technology company operating across reproductive health, diagnostics, and digital health tools. The company has an established track record in male fertility diagnostics and has previously partnered with global entities including Medical Electronic Systems (MES), iXensor, and Tyson Bio. TMSC Vietnam also developed OvumB, an AI-powered ovulation tracking and fertility support application.
For Memphasys, TMSC Vietnam’s embedded clinic relationships and regulatory familiarity materially reduce the execution risk associated with entering a new market.
Agreement structure and commercial model
Contract terms at a glance
| Detail | Year 1 | Year 2 | Total Contract Value | Notes |
|---|---|---|---|---|
| Contracted Value | A$205,000 | A$325,000 | A$530,000 | Quarterly cartridge volume growth |
| Regulatory Approval Expected | — | — | August 2026 | Class B medical device classification |
| Initial Order | 100 cartridges + 3 consoles | — | — | In-market testing and clinical preparation |
| First Commercial Order | — | September quarter 2026 | ~A$50,000 | Following regulatory approval |
A proven commercial model, replicated
The Vietnam agreement mirrors the structure Memphasys has deployed in the MENA region through its ITL partnership. Under the model, Memphasys works directly alongside TMSC Vietnam on product education, clinical positioning, and market development, while TMSC Vietnam contributes local regulatory expertise and established relationships across the Vietnamese healthcare system.
The arrangement delivers three distinct commercial advantages:
- Local regulatory navigation, with TMSC Vietnam managing the Vietnamese submission process
- Clinical adoption support, with Memphasys providing direct in-market education alongside its partner
- Contracted revenue with quarterly volume growth, providing visibility into near-term cash flows
The fact that Memphasys is replicating the same structure across multiple geographies signals scalability and repeatability in its international commercialisation approach, rather than a bespoke or one-off arrangement.
The next major ASX story will hit our subscribers first
What this means for Memphasys investors
Educational context: what is Felix™ and why does sperm selection matter?
Felix™ uses electrophoresis and size-exclusion membranes to isolate the most viable sperm cells for use in assisted reproductive procedures. The system replaces traditional centrifugation, a process that can cause cellular stress and DNA damage to sperm. The result is a faster, gentler, and more standardised sperm selection process that aims to improve IVF outcomes while reducing time in the laboratory.
For a clinic, the practical value proposition is straightforward: better sperm quality at the point of fertilisation, achieved through a repeatable, evidence-based platform rather than operator-dependent manual techniques. That clinical efficiency argument is what drives adoption and, ultimately, contracted cartridge volumes.
Near-term milestones and the broader SEA strategy
Key catalysts for investors to monitor over the next 12 to 18 months include:
- Vietnamese regulatory approval expected: August 2026
- First commercial order expected: September quarter 2026, approximately A$50,000
- In-market clinical testing already underway using the initial 100-cartridge and 3-console order
- Continued development of a broader South-East Asian distribution strategy, flagged as ongoing
Marjan Mikel, Chair of the Memphasys Commercialisation Committee
“Vietnam is exactly the kind of market Felix™ was built for… this agreement does not only open a new geography, it confirms our commercial model is globally scalable to new markets.”
Vietnam marks Memphasys’ fifth commercialisation geography, adding a contracted revenue pipeline of A$530,000 in a market forecast to grow by approximately 42% to exceed US$200 million by 2029.
Don’t Miss the Next Healthcare Breakout in Your Inbox
Get FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Over 20,000 subscribers are already staying ahead of the market with Big News Blast. Click the “Free Alerts” button to receive the next market-moving announcement the moment it hits the ASX.